Signal
Compass pathways readies FDA talks after additional phase 3 psilocybin win
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-02-17 14:21 UTCUpdated 2026-02-17 16:53 UTC
rss
clinical_trialsregulatoryfdapsychedelicscns
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Compass Pathways is positioning its synthetic psilocybin program for a regulatory transition: after reporting another Phase 3 success in treatment-resistant depression, the company is preparing to engage the FDA on a potential rolling submission strategy for COMP360.
Entities
Compass PathwaysFDACOMP360
Score total
0.98
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
Why now
- Compass reported another Phase 3 win in treatment-resistant depression
- Company plans an FDA meeting to discuss a rolling approval application for COMP360
Why it matters
- Signals a potential path from Phase 3 data to FDA filing discussions for COMP360
- Highlights continued late-stage development activity in psychedelic-based CNS therapeutics
- Rolling submission talks may shape timing and structure of a future application
LLM analysis
Topic mix: lowPromo risk: lowSource quality: high
Recurring claims
- Compass Pathways reported another Phase 3 win for its psilocybin therapy in treatment-resistant depression.
- Compass plans to meet with the FDA to discuss a rolling approval application for COMP360, a synthetic form of psilocybin.
How sources frame it
- BioPharma Dive: neutral
- Fierce Biotech: neutral
All evidence
All evidence
Compass, with Phase 3 hits, ready to take psilocybin to the FDA
BioPharma Dive · biopharmadive.com · 2026-02-17 16:53 UTC
Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the biotech’s share price up 30% and teeing up talks abou...
Fierce Biotech · fiercebiotech.com · 2026-02-17 14:21 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- BioPharma Dive (1)
- Fierce Biotech (1)
Top origin domains (this list)
- biopharmadive.com (1)
- fiercebiotech.com (1)